Novo Nordisk highlights growth building blocks; more data needed
J.P. Morgan analysts say Novo Nordisk used an investor day to outline building blocks for mid-term growth, but more data is needed to reassure investors; topline growth targets for 2026–30 were referenced as mid-single-digit.